Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients
OBJECTIVE: Identify hearing effects of a single course of intravenous (IV) aminoglycoside antibiotics (AGs) therapy in adult cystic fibrosis (CF) patients. Determine whether the change is large enough to enable a proof-of-concept study of a new drug preventing AG-associated hearing loss.
DESIGN: Retrospective case review of CF patients with sequential audiograms ± an intervening course of IV AG therapy.
STUDY SAMPLE: 84 patients with no intervening IV AG treatment, 38 patients undergoing a single course of IV AGs.
RESULTS: Using ASHA ototoxicity metrics, 45% of adult CF patients in the Single-IV group met the criteria for ototoxicity compared to 23% of the No-IV patients. Other hearing metrics including the average maximal threshold shift (TS) and average high frequency TS showed highly significant differences between groups. Testing only participants with mild or greater pre-therapy high frequency hearing loss further increased the differences between the two groups by every metric tested.
CONCLUSION: Adult CF patients exposed to a single course of IV AGs have significantly greater TS than patients without IV AG exposure. Patients with mild to moderate hearing loss prior to AG-IVs are at increased risk of developing ototoxicity from subsequent parenteral AG therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
International journal of audiology - 57(2018), 12 vom: 01. Dez., Seite 917-924 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gleser, Malcolm A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aminoglycoside |
|---|
| Anmerkungen: |
Date Completed 17.09.2019 Date Revised 17.09.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14992027.2018.1514537 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM290162378 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM290162378 | ||
| 003 | DE-627 | ||
| 005 | 20231225064130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14992027.2018.1514537 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0967.xml |
| 035 | |a (DE-627)NLM290162378 | ||
| 035 | |a (NLM)30382794 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gleser, Malcolm A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.09.2019 | ||
| 500 | |a Date Revised 17.09.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: Identify hearing effects of a single course of intravenous (IV) aminoglycoside antibiotics (AGs) therapy in adult cystic fibrosis (CF) patients. Determine whether the change is large enough to enable a proof-of-concept study of a new drug preventing AG-associated hearing loss | ||
| 520 | |a DESIGN: Retrospective case review of CF patients with sequential audiograms ± an intervening course of IV AG therapy | ||
| 520 | |a STUDY SAMPLE: 84 patients with no intervening IV AG treatment, 38 patients undergoing a single course of IV AGs | ||
| 520 | |a RESULTS: Using ASHA ototoxicity metrics, 45% of adult CF patients in the Single-IV group met the criteria for ototoxicity compared to 23% of the No-IV patients. Other hearing metrics including the average maximal threshold shift (TS) and average high frequency TS showed highly significant differences between groups. Testing only participants with mild or greater pre-therapy high frequency hearing loss further increased the differences between the two groups by every metric tested | ||
| 520 | |a CONCLUSION: Adult CF patients exposed to a single course of IV AGs have significantly greater TS than patients without IV AG exposure. Patients with mild to moderate hearing loss prior to AG-IVs are at increased risk of developing ototoxicity from subsequent parenteral AG therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Ototoxicity | |
| 650 | 4 | |a aminoglycoside | |
| 650 | 4 | |a audiogram | |
| 650 | 4 | |a cystic fibrosis | |
| 650 | 4 | |a hearing loss | |
| 650 | 7 | |a Aminoglycosides |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Zettner, Erika M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of audiology |d 2002 |g 57(2018), 12 vom: 01. Dez., Seite 917-924 |w (DE-627)NLM119085674 |x 1708-8186 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2018 |g number:12 |g day:01 |g month:12 |g pages:917-924 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14992027.2018.1514537 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2018 |e 12 |b 01 |c 12 |h 917-924 | ||